Biocompatible structures for the connection and cultivation of biological materials

The creation of biocompatible linker spheres using mineral oil emulsions with matrix materials addresses the challenges of forming complex organ systems and vascular structures in biological cultures, enabling precise spatial alignment and incorporation of functional structures.

JP2024545109AActive Publication Date: 2024-12-05EBERHARD KARLS UNIV TUBINGEN MEDIZINISCHE FAKULTAT
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024534151
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-07
Filing Date
2022-12-07
Publication Date
2024-12-05
Estimated Expiration
2042-12-07

AI Technical Summary

Technical Problem

Existing methods for culturing biological materials, such as organoids and assembroides, struggle with forming complex organ systems, vascular structures, and ductal structures, as they often fuse randomly and have irregular sizes, making spatial alignment difficult, and lack methods for incorporating immune cells or functional structures.

Method used

A method involving the creation of biocompatible linker spheres using a non-polar mineral oil emulsion with a biocompatible matrix material, such as hydrogels, to form three-dimensional structures that facilitate controlled connections and cultivation of biological materials, allowing for the formation of complex organ systems and vascular pathways.

Benefits of technology

The linker spheres enable precise spatial orientation and connection of biological aggregates, forming complex organ systems and vascular pathways, overcoming the limitations of random fusion and size irregularity in existing methods, and allowing for the incorporation of immune cells and functional structures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545109000001_ABST
    Figure 2024545109000001_ABST
Patent Text Reader

Abstract

The present invention relates to a method for producing a biocompatible structure for the connection and culture of biological materials, a method for culturing aggregates of biological materials, and the use of a biocompatible structure for the connection and culture of biological materials.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing a biocompatible structure for the connection and culture of biological materials, a method for culturing aggregates of biological materials, and the use of a biocompatible structure for the connection and culture of biological materials. [Background technology]

[0002] Traditionally, biological cells are cultured in vitro, i.e. in culture dishes, and such culture is carried out mainly by the following three methods: 1. Culture methods that are usually performed on plastic or glass surfaces coated with gels, proteins, or extracellular matrix peptides, or on uncoated plastic or glass surfaces (culture on uncoated plastic surfaces is called "adherent cell culture"), 2. Culture methods that are performed on semi-permeable membranes ("transwells"), and 3. Three-dimensional culture methods (e.g. suspension culture).

[0003] The first two methods mentioned above allow the cultivation of cells or cell mixtures derived from (primary) tissues or stem cells, and allow a certain degree of cellular maturation and functionality to be obtained, but such cells have little physiological function and it is nearly impossible to reproduce complex cell-cell and tissue interactions.

[0004] Suspension culture of cell aggregates, so-called spheroids and organoids, has the advantage that cells (usually self-organizing cells) can form complex structures and interactions. For example, spheroids can be generated by self-aggregation. In suspension culture of cell aggregates, single or mixed cells grown in adherent culture can be assembled in a container to autonomously form spherical masses or differentiate into complex organ-like organoids. An example is the retinal organoid, which forms a structured, photosensitive retina. Also, intestinal organoids can display intestinal transport functions and support in vivo intestinal villi. Other examples include brain and kidney organoids.

[0005] However, most of these organoids and spheroids remain as individual organ / tissue systems and are unable to link together to form complex organ systems.Moreover, organoids and spheroids generally fail to form the vasculature and ductal structures that extend or invade from the formed organ into other body regions during normal development.

[0006] The formation of complex organ systems as mentioned above, as well as vascular or ductal structures, can be achieved to some extent by using so-called assembloids. Assembloids are formed by fusing several organoids together into a morphologically functional unit. An example of this is the cortico-spinal-muscle assembloid, which consists of a brain region (cortex), a spinal cord spheroid (spinal cord) and muscle cells. See Anderson et al., Generation of Functional Human 3D Cortico-Motor-Assembloids. Cell, Volume 183, 2020, pages 1913-1929, e1-10.

[0007] However, assembloids, like organoids, are difficult to orient and most of them fuse randomly with each other. In addition, organoids and assembloids are often of random size and difficult to align correctly in space. One organoid or assembloid often "absorbs" another and becomes larger than the other. In addition, the possibility of obtaining organoids or assembloids that retain their structure is extremely limited. Organoids and assembloids can only be connected "in series" and cannot be connected in any other direction. Furthermore, there is no easy way to endow fused organoids or assembloids with individual cells or substances, such as immune cells, or functional structures.

[0008] In this context, the present invention aims to provide a method which makes it possible to avoid or at least reduce the disadvantages of the culture methods known in the prior art. Summary of the Invention [Means for solving the problem]

[0009] The object underlying the present invention is achieved by a method for producing a biocompatible structure for the connection and culture of biological materials ("linker spheres"), the method comprising the steps of: 1) providing a non-polar, non-water miscible biocompatible liquid, preferably mineral oil; 2) introducing a solution of a biocompatible matrix material into the biocompatible liquid to obtain an emulsion; 3) incubating the emulsion; and 4) Incubating the emulsion to form three-dimensional structures from the biocompatible matrix material to obtain linker spheres. Includes. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] According to the present invention, "biocompatibility" means the property of being non-toxic to biological materials. In the context of the linker spheres and matrix materials according to the present invention, "biocompatibility" means in particular that the matrix material is suitable as a substrate for the culture and growth of biological materials.

[0011] According to the present invention, "biological material" includes biological cells, aggregates of biological cells, organs and parts thereof.

[0012] According to the present invention, the non-polar, water-immiscible biocompatible liquid provided in step (1) is a liquid that behaves like mineral oil and is 100% immiscible in water, thereby forming the emulsion of the present invention and being non-toxic to biological materials.

[0013] The liquid provided in step (1) is preferably a "mineral oil" (CAS number: 8042-47-5; EC number: 232-455-8), i.e. a highly viscous bioreagent of such quality and purity that it can be used in the field of molecular biology, for example to layer on an aqueous solution for density gradient centrifugation (quality level: 200). Mineral oils suitable for the present invention include Sigma-Aldrich mineral oil (M5904), Carl Roth mineral oil (#8904), and Merck mineral oil (#107160; #113898). Mineral oil according to the present invention is also called "paraffin oil" or "vaseline oil". The mineral oil is preferably provided in a container, more preferably in a suitable size of a microreaction vessel, for example a vessel with a capacity of 2 ml, 1.5 ml, 0.5 ml, 0.2 ml, etc. (e.g. an "Eppendorf" tube).

[0014] According to the present invention, the "matrix material" is a mixture of molecules present in liquid form in step 2, which can be transformed into a tissue-like solid form by the action of physical or chemical phenomena. The matrix material in solid form provides a biocompatible structure, preferably a network-like structure, in which biological materials can be cultured. Examples of matrix materials suitable for the present invention include hydrogels, basement membrane-like matrices (e.g., Matrigel; Matrigel is suitably rich in laminin), and other biocompatible gel-like materials.

[0015] The introduction of the solution of the biocompatible matrix material into the mineral oil in step (2) is carried out using a suitable dispensing device (e.g., a pipette). Because the aqueous matrix material is fluid, it is preferably introduced into the mineral oil in the form of droplets to form an emulsion.

[0016] The size of the linker spheres according to the present invention can be easily controlled by varying the volume of matrix material: a larger volume of matrix material will result in a larger linker sphere, and a smaller volume of matrix material will result in a smaller linker sphere.

[0017] According to the invention, in step (3), incubation is carried out for a period of time that allows for the formation of linker spheres, preferably for at least 10 seconds and up to 60 minutes.

[0018] The exact incubation time can be determined by one skilled in the art and depends on the type of gelation process. For example, Matrigel is incubated at high temperatures. Other hydrogels require "crosslinkers" or similar binding chemicals. Thus, incubation can last from a few seconds to a few minutes (up to an hour).

[0019] In step (4) of the method of the present invention, it is presumed that the interfacial effect between the aqueous biocompatible matrix material and the surrounding mineral oil causes the aqueous biocompatible matrix material in the emulsion to assume a spherical shape, hence the name "linker spheres."

[0020] In this way, the objectives underlying the present invention can be fully achieved.

[0021] The inventors have found that by utilizing the method of the present invention, biocompatible structures in the form of linker spheres can be produced, which are valuable tools for tissue engineering that can at least partially or completely overcome the shortcomings of the prior art.

[0022] According to the invention, the linker sphere obtained by the method of the invention is suitable for culturing biological materials inside and / or on its surface and is configured to perform such culturing. Furthermore, the linker sphere is suitable for connecting biological materials and is configured to perform such a connection, since it acts as a bridge or a communication channel between different types of biological materials or aggregates thereof ("linker" = connection, "sphere" = sphere). Furthermore, since the linker sphere is capable of culturing biological materials, the biological materials or parts thereof can grow through the inside of the linker sphere or can grow on the surface of the linker sphere. Thus, a connection can be established between a first biological material or aggregates thereof and a second biological material or aggregates thereof, and further biological materials or aggregates thereof, via the linker sphere.

[0023] Furthermore, the linker spheres provide a physiological environment for biological materials that allows the formation of vascular and ductal pathways that extend or penetrate from one organ to another biological region during the development of the organism. The linker spheres obtained according to the present invention are capable of reproducing complex cell-cell, tissue-tissue and organ-organ interactions. Thus, the linker spheres are particularly suitable for the study of complex biological structures, such as organs and organ systems.

[0024] In one embodiment of the method of the present invention, the biocompatible matrix material is a basement membrane-like matrix.

[0025] According to the present invention, a "basement membrane-like matrix" is a complex mixture of biomolecules used as a growth substrate, i.e. as a matrix or cell substrate in three-dimensional cell culture and three-dimensional tissue engineering. Basement membrane-like matrix is ​​a secretion purified from the mouse sarcoma cell line Engelbreth-Holm-Swarm (EHS cells), and its composition resembles the extracellular matrix of the basement membrane of animal cells. Basement membrane-like matrix contains laminin, entactin, collagen, heparan sulfate proteoglycan, etc. This approach has the advantage of employing a particularly suitable biocompatible matrix material according to the present invention. The basement membrane-like matrix forms a networked gel-like structure or hydrogel by polymerization of the proteins contained in its composition at about 37°C, but becomes liquid at low temperatures, e.g. 4°C. Basement membrane-like matrix is ​​capable of forming a complex and physiological three-dimensional cell network structure, as compared to polylysine-coated cell culture matrices. A summary of basement membrane-like matrices is described, for example, in Hughes et al: "A complex protein mixture required for optimal growth of cell culture" in Proteomics, Volume 10, Issue 9, 2010, ISSN 1615-9861, pp. 1886-1890.

[0026] Trade names of basement membrane-like matrices suitable for the present invention include Matrigel (Corning Life Sciences), BME, and EHS matrix.

[0027] In one embodiment of the present invention, in step (2) of the method of the present invention, a solution of growth factor reduced (GFR) basement membrane-like matrix is ​​introduced.

[0028] This approach has the advantage that a matrix is ​​used in which growth factors (e.g. EGF) that may affect the cells that compose the aggregates are reduced. For example, neurons are preferably cultured on such a matrix to reduce such effects. A suitable growth factor-reduced basement membrane-like matrix according to the present invention is that sold under the trade name Corning® Matrigel® Growth Factor-Reduced (GFR) Basement Membrane Matrix, LDEV Free (product number: 354230, Corning Life Sciences).

[0029] In one embodiment of the invention, step (3) of the method of the invention involves treating the emulsion to solidify the biocompatible matrix material, which is preferably done by heating the emulsion, preferably at about 37°C, and more preferably for about 15-30 minutes.

[0030] This approach has the advantage that the linker spheres can be converted into a manageable solid form suitable for culturing purposes by crosslinking the proteins contained in the biocompatible matrix material or its composition. Upon solidification or crosslinking, a solid hydrogel or gel-like structure is formed, which allows the incubation and growth of biological material within it. Heat treatment can be conveniently performed by placing the reaction vessel containing the emulsion in a water bath.

[0031] In a further embodiment of the method of the present invention, the solution of biocompatible matrix material comprises a cell culture medium.

[0032] By this means, the physiological conditions required for the linker spheres are created when they are used to culture biological materials immediately after their preparation. Any culture medium can be suitably used in the present invention, and the specific culture medium is selected by the expert depending on the biological material to be cultured or connected with the linker spheres. For example, cell culture media suitable for culturing astrocytes are N2 medium and "B27-based retinal differentiation medium" (BRDM medium).

[0033] According to a further embodiment of the invention, the solution of biocompatible matrix material comprises biological material, preferably biological cells.

[0034] According to this approach, the desired biological material or biological cells are already incorporated into the linker sphere during its production. Such linker spheres containing biological material can be used as independent culture units or can be used to connect units or aggregates of biological material.

[0035] In one embodiment of the present invention, the solution of biocompatible matrix material includes a dye.

[0036] This has the advantage of improving the visibility of the linker spheres, making them easier to handle and use in subsequent applications. Suitable dyes are biocompatible dyes, which are dissolved, for example, in a buffer.

[0037] In one embodiment of the invention, in step (2) of the method of the invention, the solution of biocompatible matrix material is introduced into the mineral oil as flowable droplets, preferably by means of a pipette tip.

[0038] By this means, the linker spheres of the invention can be produced particularly efficiently. In the production of linker spheres, a pipette with a solution of a biocompatible matrix material aspirated into its tip is first held just above the oil surface. When using a micropipette, it is preferable to push it to the first stop. This action forms a droplet at the tip of the pipette. Next, the pipette tip is immersed in the oil, causing the droplet to detach from the tip, sink into the oil, and sink to the bottom of the reaction vessel.

[0039] In a further development of the method of the invention, step (4) is followed by step 5) of isolating the linker spheres from the emulsion.

[0040] This procedure has the advantage that the linker spheres can be separated from the emulsion and prepared for further use.

[0041] In one embodiment of the method of the present invention, step (5) is followed by a step 6) of washing the isolated linker spheres, which is preferably carried out with an aqueous solution, more preferably with a cell culture medium.

[0042] This procedure has the advantage that residual mineral oil can be separated from the linker spheres, and this washing step can be repeated to completely remove excess mineral oil from the linker spheres so that residual oil does not adversely affect subsequent cultures.

[0043] In another embodiment of the invention, after step (4) and before step (5), an additional step is performed: 4') introducing an aqueous solution, preferably an aqueous buffer, into the emulsion to form an aqueous phase and transferring the linker spheres into this aqueous phase.

[0044] In this way, a two-phase system consisting of an oil phase and an aqueous phase is created. The linker spheres formed in aqueous form can be easily isolated and purified by transferring them from the oil phase to the aqueous phase. Generally, any commercially available biocompatible buffer, such as PBS buffer, can be used suitably. The specific buffer is selected by the expert depending on the specific biological material to be cultured or connected.

[0045] In another embodiment of the invention, the isolated linker spheres, which may be washed, are transferred to a culture vessel, preferably a culture dish.

[0046] By this means, the linker spheres can be placed in an environment where they can be directly used for culturing and connecting biological materials, for example, in a commercially available culture dish such as a Petri dish, and the type of culture dish is selected depending on the specific application of the linker spheres.

[0047] In one embodiment of the method of the present invention, the isolated linker spheres, which may be washed or transferred, are preferably cultured at about 37° C., more preferably under about 20 vol% O2, even more preferably under about 5 vol% CO2, more preferably for at least about 12 hours.

[0048] This procedure has the advantage that parameters specifically suited for the culture of linkerspheres can be utilized.

[0049] Another aspect of the invention is a method for culturing and / or connecting aggregates of biological material, comprising the steps of: 1) contacting an aggregate of biological material with a biocompatible structure for connecting and culturing biological material ("linker sphere") in a suitable medium to obtain a complex of the aggregate of biological material and the linker sphere; 2) A step of culturing a complex of the aggregate of the biological material and the linker sphere. Including, The linker sphere is obtained by the production method of the present invention. It concerns the method.

[0050] The features, properties, developments and advantages of the production method of the invention apply analogously to the culture method of the invention.

[0051] According to the present invention, "culturing" of the complex of biological material aggregates and linker spheres is carried out under standard cell culture conditions, e.g., in a nutrient medium in an incubator at about 37°C and, if applicable, under 5% CO2.

[0052] By using the linker sphere of the present invention, aggregates of biological materials can be connected or fused to each other at a predetermined distance determined by the linker sphere. In one embodiment of the present invention, two or more linker spheres can be placed between the aggregates, and the number of linker spheres placed between the aggregates can be any number. The linker sphere ensures a certain distance, which ensures spatial separation of the aggregates to be fused, making it difficult for the aggregates to grow by penetrating each other, thereby preventing one aggregate from growing too much compared to another aggregate. In addition, by using the linker sphere, multiple aggregates can be connected to one aggregate, for example, a four-leaf clover structure can be obtained.

[0053] By connecting or fusing multiple aggregates via multiple linker spheres, theoretically infinitely large and complex arrangements can be formed in a manner similar to a building block approach ("LEGO system").

[0054] Linker spheres can also be used to create pathways connecting aggregates of biological materials, such as perfusable blood vessels, nerve pathways, or extracellular matrix (ECM) structures. These can also be combined. Such pathways can be provided as additional spheroid structures (e.g., vascular organoids) or can be embedded in the linker spheres during the linker sphere production process. Furthermore, fusion of multiple linker spheres containing different types of cells can be easily performed.

[0055] The linker spheres can include any ECM structure and therefore can mimic biological / pathway structures.

[0056] Even if the aggregates are of different sizes, they can be easily fused together via the linker spheres by simply linking each of the aggregates to the linker spheres of the present invention, and then a pathway system can be placed between the aggregates.

[0057] In one embodiment of the culture method of the present invention, the biological material aggregates are cut prior to contacting with the linker spheres, preferably cut with microscissors, and more preferably, the biological material aggregates are contacted with the linker spheres at their cut surfaces.

[0058] By this means the shape and size of the aggregates can be tailored to suit the linker spheres and / or the desired connections. The cut surfaces provide particularly good contact areas, allowing for reliable and good connections to be made with the aggregates of biological material.

[0059] In one embodiment of the culture method of the present invention, the culture is carried out at about 37° C., preferably under about 20% O 2 , and more preferably under about 5% CO 2 .

[0060] This approach has the advantage of providing the skilled artisan with culture conditions which have been proven to be particularly effective according to expert knowledge.

[0061] In another embodiment of the culture method of the invention, the aggregates of biological material are organoids and / or spheroids and / or assembloids.

[0062] This approach has the advantage of reducing or even avoiding the drawbacks known in the prior art for organoids and assembloids. By placing linker spheres between aggregates of biological material, tissues that may be of different types do not directly fuse with each other, which is usually not seen in living organisms. In addition, by inserting linker spheres, the spatial orientation of the aggregates can be determined precisely and at will. On the other hand, direct fusion usually results in random fusion without directionality, especially when aggregates of different sizes are used. Furthermore, the method of the present invention is the first to successfully orient multiple aggregates "in series".

[0063] In one embodiment of the culture method of the present invention, the aggregate of biological material is selected from the group consisting of retinal organoids, vascular organoids, cerebral organoids and neurospheroids.

[0064] By this means, the culture method of the present invention can be applied to biological aggregates that naturally exist in complex environments, and the present invention has made it possible for the first time to reproduce biological aggregates in such complex environments. "Retinal organoids" are three-dimensional structures of retinal cells induced to differentiate from pluripotent stem cells, and have stratification, cell-cell interactions, and cell type-specific diversity that mimic the human embryonic retina. In addition, retinal organoids can also form light-sensitive photoreceptors with specialized structures of retinal cells (inner and outer segments). "Vascular organoids" are three-dimensional structures that can be formed from pluripotent stem cells, and contain vascular cells such as endothelial cells and pericytes. Vascular organoids self-organize into three-dimensional capillary networks surrounded by a basement membrane. "Brain organoids" are organoids formed from pluripotent stem cells, and can reflect the organization and cellular diversity of specific brain regions. For example, thalamic organoids contain neurons found in the thalamus. According to the present invention, a "neurospheroid" is a spherical assembly of neural cells (neurons, glial cells, and their precursor cells) that can be prepared from pluripotent stem cells. This assembly may contain organized regions (e.g., neural rosettes or cortex-like regions) and unorganized regions.

[0065] In one embodiment of the culture method of the present invention, the biological material aggregate comprises astrocytes, preferably astrocytes derived from embryonic pluripotent stem cells (iPSCs).

[0066] This approach has the advantage of making available cells of particular importance for tissue engineering, and in particular cells of great interest in neuroscientific research and drug testing, said stem cells preferably being of human or animal origin.

[0067] In one embodiment of the present invention, in the culture method of the present invention, step (2) is followed by step (3), in which steps (1) and (2) are repeated.

[0068] By this means, tissue structures with no length limit can be produced, and any number of linker spheres and biomaterial aggregates can be connected. Thus, according to the present invention, steps (2) and (3) can be repeated at least once, at least twice, at least three times, at least four times, ... at least 10 times, at least 20 times, at least 100 times, etc.

[0069] Another aspect of the present invention relates to the use of the linker spheres obtained by the manufacturing method of the present invention for the connection and culture of biological materials.

[0070] The features, properties, developments and advantages of the production and culture methods of the invention apply equally to the uses of the invention.

[0071] The features mentioned above and those to be described hereinafter may not only be used in the combinations specifically mentioned, but may also be used in other combinations or alone without departing from the scope of the invention.

[0072] The present invention will now be described in more detail with reference to the following examples, in which the features described are not only applicable in relation to the specific examples below, but are also considered to belong to the invention in their individual forms. [Brief description of the drawings]

[0073] Reference is made to the accompanying drawings which show: [Figure 1] FIG. 1 is a schematic diagram showing the production of a linker sphere of the present invention. [Diagram 2] (a) shows a schematic diagram of the astrolinker, and (b) to (e) show microscopic images. [Diagram 3] A schematic diagram showing the connection process between whole or half-cut organoids and linker spheres (upper panel) and microscopic images of the ligation products (lower panel) are shown. [Figure 4](a) The connection process between retinal organoids and linker spheres, (b) floating culture of the connection products, (c) extension of axons from retinal organoids into the inside of the linker spheres, (d) the connection products obtained by single connection, and (e) microscopic images of the connection products obtained by double connection. [Figure 5-6] Shown are microscopic images of double connections of linker spheres with neurospheres and retinal organoids. [Figure 7] Shown are microscopic images of astrocyte dual connections with neurospheres and retinal organoids. [Figure 8] FIG. 1 shows a schematic diagram of a composite model of the optic nerve using the linker sphere of the present invention. [Figure 9] FIG. 1 is a schematic diagram showing the support of angiogenesis by the linker spheres of the present invention. [Figure 10] FIG. 1 is a schematic diagram showing the concept of multiple connections. EXAMPLES

[0074] 1. Fabrication of Linkerspheres overview Figure 1 shows a schematic diagram outlining the production of linkerspheres. In the first step, shown at the far left, mineral oil is placed in a reaction vessel. Liquid biocompatible matrix material, which may be mixed with biological materials such as biological cells and / or culture medium, is drawn up into a pipette.

[0075] In the next step, a drop of the solution of the biocompatible matrix material is introduced into the mineral oil by bringing the tip of the pipette into contact with the surface of the mineral oil and then expelling the drop from the pipette, allowing it to sink to the bottom of a reaction vessel filled with mineral oil.

[0076] In the next step, the reaction vessel containing the formed emulsion is heat treated, for example by placing the reaction vessel in a water bath and incubating it at 37°C for 30 minutes. The proteins contained in the biocompatible matrix material are cross-linked, the biocompatible matrix material solidifies, and a gel-like structure or hydrogel is formed, which is called a "linker sphere."

[0077] In the final step of FIG. 1, the linker spheres are washed and then transferred to culture medium.

[0078] detail Cell-containing linker spheres Using astrocyte-laden linker spheres, known as "Astrolinkers," as an example, technical details regarding the preparation of cell-laden linker spheres are described below.

[0079] The materials needed are as follows: Growth factor reduced Matrigel (Corning Life Sciences) Mineral oil (Sigma-Aldrich) N2 medium (DMEM / F12 medium supplemented with Glutamax, 2% hormone mix, 1% non-essential amino acids (NEAA), and 1% antibiotic-antimycotic (Anti-Anti); all from Thermo Fisher Scientific) BRDM medium (Glutamax, DMEM / F12 (3:1) medium supplemented with 2% vitamin A-free B27, 1% amino acids, and 1% NEAA; all from Thermo Fisher Scientific) · ASC ++ Culture medium (N2 medium + 10ng / ml epidermal growth factor (EGF) + 10ng / ml fibroblast growth factor 2 (FGF2)) BRDM FBST (DMEM / F12 (3:1) medium supplemented with Glutamax, 10% FBS, 2% B27, 1% amino acids, 1% NEAA (all from Thermo Fisher Scientific) and 100 μM taurine) Magnesium / calcium-free PBS (PBS -- , Thermo Fisher Scientific) · TrypLE (Thermo Fisher Scientific) 1.5ml reaction tube 15ml conical tube Heating block for tubes Non-adherent 24-well or 48-well plates 1000μl pipette tip with the tip cut off (with scissors) 37℃ water bath A bucket of ice Micro scissors (FST) Non-tissue culture treated V-type 96-well plates (Sarstedt)

[0080] Linker spheres containing astrocytes are prepared as follows.

[0081] Human iPSC-derived astrocytes were differentiated according to the method of Krencik et al. (2011) (Directed differentiation of functional astroglial subtypes from human pluripotent stem cells, Nat. Protoc. 6(11): 1710-7, doi:10.1038 / nprot.2011.405). For each experiment, astrocytes were thawed and cultured in 24- or 48-well plates as ASCs. ++ Culture ASCs in medium 6-7 days before starting this experiment. ++ Treat astrocytes with 1ng / ml CNTF in culture medium and change the medium every other day. At least one well that reached confluence was replaced with PBS. --Wash very carefully with 500 ml of TrypLE and incubate at 37°C for 2 minutes to detach the astrocytes from the wells. After confirming that the cells are single cells, add twice the volume of N2 medium as the TrypLE-containing medium to stop the reaction. Transfer the cells to a 15 ml conical tube and centrifuge at 1500 x g for 2 minutes. Discard the supernatant, resuspend the cells in an appropriate amount of N2 medium, dilute 1:1 with trypan blue, and count the number of cells (in approximately 500 µl to 1000 µl) on a Neubauer hemocytometer to identify dead cells. Transfer the required number of cells to a 1.5 ml Eppendorf tube. 10,000 cells are required to prepare one astrocyte with a size of 2.5 µl per unit.

[0082] The collected cells are then pelleted again by centrifugation at 800 x g for 2 minutes. The supernatant is carefully discarded as completely as possible. The cell pellet is then resuspended in cold BRDM medium to obtain 1.25 μl of cell suspension per astrolinker (e.g., to obtain 10 astrolinkers from 100,000 cells, use 10 μl of medium). The resulting cell suspension is then stored on ice. Growth factor-reduced Matrigel (thawed overnight in the refrigerator) is added to the chilled cell suspension in a 1:1 ratio, and the resulting solution is mixed gently and thoroughly, taking care not to introduce air bubbles. To make it easier to see the astrolinkers in the later steps, the Matrigel can be stained with ink or other dyes. In this experiment, PBS -- A 5% ink diluted 1:1000 with was used.

[0083] Before starting the next step, add about 50 μl of mineral oil to a 1.5 ml reaction tube (prepare one tube per Astrolinker) and store at room temperature until use.

[0084] Next, transfer 2.5 μl of the astrocyte and Matrigel mixture into a reaction tube containing mineral oil using a thin-walled 10 μl pipette tip (preferably pre-cooled). To create the astrolinker, first hold the pipette with 2.5 μl of the astrocyte and Matrigel mixture aspirated into the tip just above the oil surface and push it to the first stop. This action forms a droplet at the tip of the pipette. Next, immerse the pipette tip and the droplet at its tip into the oil solution, so that the droplet detaches from the tip and sinks into the oil solution. Discard the remaining liquid in the pipette. Place the tube containing the astrolinker on a heating block (37 °C) as quickly as possible to allow rapid solidification. This action is necessary to prevent the cells from dispersing unevenly in the droplet. Next, incubate the tube at 37 °C for 15 to 30 minutes.

[0085] After incubation, add approximately 200 μl of pre-warmed PBS. -- (37°C). This operation is performed to transfer the formed linker spheres from the oil phase to the aqueous phase. -- (and as little oil as possible) in PBS pre-warmed to 37℃ -- The linker spheres are then washed and the oil solution is removed. This washing step can be repeated to remove any residual oil. The washed astrocytes are then transferred to a Petri dish (e.g., 6 cm) containing ASC solution that has been pre-warmed to 37°C. ++ Transfer to a non-tissue culture treated 48-well plate containing 250 μl of medium. Again, use a cut pipette tip. Incubate astrocytes at 37 °C with 20% O2 and 5% CO2 at least overnight, changing the medium (half the volume) every 2-3 days until use or fixation.

[0086] Figure 2a shows a schematic diagram of an astrolinker. Figure 2b shows an astrolinker (astrocyte-loaded linkersphere) after 1 day of culture. Figure 2c shows an astrolinker loaded with astrocytes pre-transfected with a lentiviral construct (Lenti-GFAP-GFP) expressing green fluorescent protein (GFP) under the control of the glial fibrillary acidic protein (GFAP) promoter. Figures 2d and 2e show three-dimensional reconstructions of a portion of an astrolinker loaded with astrocytes expressing GFP under the control of the GFAP promoter as shown in Figure 2c. Figure 2d shows a fluorescent image stained with magenta, and Figure 2e shows an image with height indicated in pseudocolor.

[0087] Linker spheres without cells Cell-free linker spheres are prepared similarly to the protocol described above.

[0088] Instead of astrocytes, only medium (e.g., BRDM medium) is added to the GFR-Matrigel. All subsequent steps are the same. The acellular linker spheres can be cultured in medium or buffer pre-warmed to 37°C, and any type of medium or buffer is acceptable.

[0089] 2. Fabrication of Double Connections Human iPSC-derived retinal organoids (ROs) were differentiated according to previously published protocols (Zhong et al. 2014, Achberger et al. 2019) and selected 40–80 days after differentiation induction.

[0090] On day 1 (the day after the linker spheres are made), before the connection between the retinal organoids and the linker spheres is made, the retinal organoids are cut in two with microscissors and transferred to a non-tissue culture treated V-bottom 96-well plate. Each well is filled with one half of the retinal organoid. Then, to each well containing the retinal organoids, add the astrolinker or acellular linker spheres using a 1000 μl pipette tip. Using a fine needle or a small pipette tip, place the retinal organoids and the linker spheres under the microscope. The retinal organoids are positioned so that the cut surface is in direct contact with the astrolinker / linker sphere. Then, place the plate very carefully in an incubator (37 °C, 20% O2, 5% CO2), taking care not to disturb the positioning of the retinal organoids.

[0091] A triple connection can also be made the next day or at a later date.

[0092] 3. Fabrication of Triple Junction The next day, select thalamic organoids (TOs) differentiated according to a previously published protocol (Xiang 2019) 40–80 days after differentiation induction. Add one thalamic organoid to each of the V-bottom 96-well plates containing the double connections (astrolinker / linkerspheres + retinal organoids) described above. Again, create triple connections by using a fine needle or small pipette tip to place the thalamic organoids directly on the side of the astrolinker / linkersphere opposite to the side where the retinal organoids were attached. This operation is crucial to connect cells to each other via the astrolinker, rather than directly to each other. Leave the plate at 37 °C overnight in an incubator with 20% O2 and 5% CO2, taking care not to move the organoids.

[0093] Culturing of the triple junction can also be performed at a later date.

[0094] A schematic of the connection process is shown in Figure 3. The scale bars in the two microscope images at the bottom of the figure correspond to a distance of 1000 μm.

[0095] 4. Culturing Triple Junctions The next day, prepare a non-tissue culture treated 48-well plate with 250 μl of BRDM medium pre-warmed to 37 °C. Transfer the triplicate connected organoids (using a 1000 μl pipette tip with the tip cut off) to this non-tissue culture treated 48-well plate and incubate at 37 °C under 20% O2 and 5% CO2. To observe the axonal projections between the retinal and thalamic organoids, observe the astrolinkers under a microscope. For this purpose, the retinal organoids can be stably transduced with GFP (e.g., using a lentiviral vector). Medium exchange of the double- or triple-connected organoids is performed every 2-3 days with warmed BRDM medium (250 μl per well, half medium exchange).

[0096] Figure 4b shows microscopic images of the results of the connection process between linker spheres and retinal organoids. Figure 4b shows the complex of linker spheres and retinal organoids in floating culture. Figure 4c shows the extension of neurites from retinal organoids to linker spheres. Figure 4d shows the result of a simple connection between retinal organoids and linker spheres. Figure 4e shows the result of a double connection. Astrocytes were labeled with GFP and stained in a similar manner.

[0097] Figure 5 shows a double connection of a linker sphere with a neurosphere connected on one side and a retinal organoid connected on the other side. The neurosphere is connected to the retinal organoid via neural pathways extending through the linker sphere. Figure 6 shows GFP-labeled cells of a retinal organoid with axonal projections inside the neurosphere. The GFP-labeled cells are positive for the ganglion cell marker NEFM.

[0098] Figure 7 shows the dual connection of an astrolinker with a neurosphere connected to one side and a retinal organoid connected to the other side. The neurosphere is connected to the retinal organoid via neural pathways extending through the linker sphere.

[0099] Figure 8 shows a schematic diagram of a composite model of the optic nerve, for example for modeling glaucoma, which is composed of a retinal organoid containing retinal ganglion cells, two linkers filled with oligodendrocytes (myelinating part of the optic nerve), astrocytes (intraretinal part of the optic nerve), and a brain organoid patterned, for example, into the diencephalon or posterior thalamus.

[0100] FIG. 9 shows a schematic diagram illustrating how linker spheres can be used to support angiogenesis, for example, by connecting tissue organoids and vascular organoids.

[0101] Figure 10a and 10b show the concept of multiple connections. The use of linker spheres allows multiple organoids to be combined with various connection concepts (e.g., neuronal connections, angiogenesis, etc.). Linker spheres have the potential to facilitate the growth / assembly of multiple organoids and multicellular tissue complexes (e.g., nerve growth, angiogenesis, etc.).

Claims

1. A method for producing a biocompatible structure for the connection and culture of biological materials ("linker spheres"), comprising the steps of: 1) providing a non-polar, non-water miscible biocompatible liquid; 2) introducing a solution of a biocompatible matrix material into the biocompatible liquid to obtain an emulsion; 3) incubating the emulsion; and 4) Incubating the emulsion to form three-dimensional structures from the biocompatible matrix material to obtain linker spheres. A method comprising:

2. The method of claim 1 , wherein the non-polar, water-immiscible, biocompatible liquid is mineral oil.

3. The method of claim 1 or 2, wherein the biocompatible matrix material is a basement membrane-like matrix.

4. 2. The method of any one of the preceding claims, wherein in step (2) a solution of a basement membrane-like matrix having reduced growth factors is introduced.

5. 2. The method of any one of the preceding claims, wherein in step (3), the emulsion is treated to solidify the biocompatible matrix material.

6. 6. The method of claim 5, wherein the treatment comprises exposure to heat, preferably to about 37° C., more preferably exposure to heat for about 15-30 minutes.

7. 2. The method of any one of the preceding claims, wherein the solution of biocompatible matrix material comprises a cell culture medium.

8. 2. The method of any one of the preceding claims, wherein the solution of biocompatible matrix material comprises biological cells.

9. 2. The method of any one of the preceding claims, wherein the solution of biocompatible matrix material comprises a dye.

10. 2. The method of any one of the preceding claims, wherein in step (2), the solution of the biocompatible matrix material is introduced into the mineral oil as flowable droplets.

11. The method of claim 10 , wherein introducing the solution of the biocompatible matrix material into the mineral oil as flowable droplets is performed with a pipette tip.

12. 2. The method of any one of the preceding claims, wherein step (4) is followed by step 5) of isolating the linker spheres from the emulsion.

13. The method according to claim 12, wherein step (5) is followed by step 6) of washing the isolated linker spheres, the washing being preferably carried out with an aqueous solution, more preferably with a cell culture medium.

14. The method according to claim 12 or 13, further comprising the step of: 4') introducing an aqueous solution, preferably an aqueous buffer solution, into the emulsion to form an aqueous phase and transferring the linker spheres into the aqueous phase, after step (4) and before step (5).

15. The method according to any one of claims 12 to 14, wherein the isolated linker spheres, which may have been washed, are transferred to a culture vessel, preferably a culture dish.

16. The isolated linker spheres, which may be washed or transferred, are preferably incubated at about 37° C., more preferably at about 20 vol.% O. 2 More preferably, about 5 vol% CO 2 The method according to any one of claims 12 to 15, wherein the culture is carried out under reduced pressure, more preferably for at least about 12 hours.

17. 1. A method for culturing an aggregate of biological material, comprising: 1) contacting an aggregate of biological material with a biocompatible structure for connecting and culturing biological material ("linker sphere") in a suitable medium to obtain a complex of the aggregate of biological material and the linker sphere; 2) A step of culturing a complex of the aggregate of the biological material and the linker sphere. Including, The method, wherein the linker sphere is obtainable by the method according to any one of claims 1 to 16.

18. 18. The method of claim 17, wherein the biological material aggregates are cut prior to contacting with the linker spheres, preferably using microscissors.

19. The method of claim 18, wherein the aggregates of biological material are contacted with the linker spheres at their cut surfaces.

20. The culture is carried out at about 37° C. and preferably at about 20 vol% O 2 More preferably, about 5 vol% CO 2 The method according to any one of claims 17 to 19, wherein the method is carried out under

21. The method according to any one of claims 17 to 20, wherein the aggregate of biological material is an organoid and / or a spheroid and / or an assembloid.

22. 22. The method of claim 21, wherein the aggregate of biological material is selected from the group consisting of retinal organoids, vascular organoids, cerebral organoids and neurospheroids.

23. The method according to any one of claims 17 to 21, wherein the aggregate of biological material comprises astrocytes, preferably astrocytes derived from induced pluripotent stem cells (iPSCs).

24. The method according to any one of claims 15 to 23, further comprising, after step (2), performing step (3) of repeatedly performing steps (1) and (2).

25. Use of a linker sphere obtained by the method according to any one of claims 1 to 16 for the connection and culture of biological materials.

Citation Information

Patent Citations

  • Production of cell embedded in collagen gel bead

    JP1989071487A

  • Three-dimensional hierarchic cell coculture method

    WO2010067904A1